Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to market Micafungin injection, 50 mg/vial and 100 mg/vial, single-dose vials (USRLD: Mycamine).Micafungin injection is indicated to treat a variety of fungal infections. It is also used to prevent fungal infections in patients who are having a stem cell transplant. The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara, India.Micafungin injection had annual sales of $99 million in the United States according to IQVIA data (IQVIA MAT Aug 2022). The group now has 329 approvals and has so far filed over 428* Abbreviated New Drug Applications (ANDAs) since the commencement of the filing process in FY 2003-04.
, CDSCO.jpg)
